The recent development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, as well as alpelisib (Piqray), a phosphoinositide 3-kinase (PI3K) inhibitor, has changed the way patients with HR-positive MBC are treated.
Amanda Manoogian, PharmD, BCOP, Clinical Pharmacy Coordinator Specialty Pharmacy - Clinical Services (Partners Healthcare)
Advertisement
Articles by Amanda Manoogian, PharmD, BCOP, Clinical Pharmacy Coordinator Specialty Pharmacy - Clinical Services (Partners Healthcare)
Advertisement
Latest Updated Articles
Oral Therapies for Hormone Receptor – Positive Breast CancersPublished: December 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
Recognizing Immunizing Pharmacists in the Community
5
